IL301385A - TYK2 inhibitors and their use - Google Patents

TYK2 inhibitors and their use

Info

Publication number
IL301385A
IL301385A IL301385A IL30138523A IL301385A IL 301385 A IL301385 A IL 301385A IL 301385 A IL301385 A IL 301385A IL 30138523 A IL30138523 A IL 30138523A IL 301385 A IL301385 A IL 301385A
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
stereoisomer
solvate
acceptable salt
Prior art date
Application number
IL301385A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of IL301385A publication Critical patent/IL301385A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL301385A 2020-09-16 2021-09-16 TYK2 inhibitors and their use IL301385A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063079217P 2020-09-16 2020-09-16
PCT/US2021/050649 WO2022060973A1 (en) 2020-09-16 2021-09-16 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
IL301385A true IL301385A (en) 2023-05-01

Family

ID=78086111

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301385A IL301385A (en) 2020-09-16 2021-09-16 TYK2 inhibitors and their use

Country Status (9)

Country Link
US (1) US20230357273A1 (https=)
EP (1) EP4214215A1 (https=)
JP (1) JP7824938B2 (https=)
KR (1) KR20230069984A (https=)
CN (1) CN117279922B (https=)
AU (1) AU2021345181A1 (https=)
CA (1) CA3192621A1 (https=)
IL (1) IL301385A (https=)
WO (1) WO2022060973A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CA3245808A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. TYK2 INHIBITORS AND THEIR USES
CN119487037A (zh) * 2022-03-16 2025-02-18 阿鲁米斯股份有限公司 Tyk2抑制剂及其用途
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
JP2026512838A (ja) 2023-03-31 2026-04-21 北京普祺医薬科技股▲分▼有限公司 大環化合物、医薬組成物及びその使用
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
ES2902995T3 (es) * 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN113348021B (zh) * 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
JP2022519696A (ja) * 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands

Also Published As

Publication number Publication date
AU2021345181A9 (en) 2024-06-20
CN117279922B (zh) 2025-12-19
JP2023541203A (ja) 2023-09-28
AU2021345181A1 (en) 2023-05-04
JP7824938B2 (ja) 2026-03-05
WO2022060973A1 (en) 2022-03-24
US20230357273A1 (en) 2023-11-09
CN117279922A (zh) 2023-12-22
EP4214215A1 (en) 2023-07-26
CA3192621A1 (en) 2022-03-24
KR20230069984A (ko) 2023-05-19

Similar Documents

Publication Publication Date Title
CN113490664B (zh) Tyk2抑制剂和其用途
JP7824938B2 (ja) Tyk2阻害剤およびその使用
KR102899985B1 (ko) Tyk2 억제제 및 그의 용도
WO2023178234A1 (en) Tyk2 inhibitors and uses thereof
JP2025509594A (ja) Tyk2阻害剤およびその使用
HK40105557B (zh) Tyk2抑制剂及其用途
HK40105557A (zh) Tyk2抑制剂及其用途
HK40120037A (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40119624B (en) Tyk2 inhibitors and uses thereof
HK40120037B (en) Tyk2 inhibitors and uses thereof
HK40065275A (zh) Tyk2抑制剂和其用途